Comparison of warfarin versus antiplatelet therapy after surgical bioprosthetic aortic valve replacement.
Christina ChristerssonStefan K JamesLars LindhagenAnders AhlssonÖrjan FribergAnders JeppssonElisabeth StåhlePublished in: Heart (British Cardiac Society) (2019)
In patients discharged after bioSAVR, warfarin exposure as compared with SAPT exposure was associated with lower long-term risk of ischaemic stroke and thromboembolic events, and with a higher incidence of bleeding events but with similar mortality.
Keyphrases
- aortic valve replacement
- antiplatelet therapy
- atrial fibrillation
- aortic stenosis
- aortic valve
- ejection fraction
- transcatheter aortic valve implantation
- end stage renal disease
- percutaneous coronary intervention
- acute coronary syndrome
- newly diagnosed
- venous thromboembolism
- direct oral anticoagulants
- risk factors
- chronic kidney disease
- peritoneal dialysis
- mitral valve
- oral anticoagulants
- type diabetes
- left ventricular